Suppression of HIV replication in vitro by CpG and CpG conjugatd to the non toxic B subunit of cholera toxin

Current HIV Research

Volumn 6, Issue 3, 2008, Pages 230-238

  Nowroozalizadeh, Salma ^a,b   Janssson, Marianne ^a,b   Adamsson, Jenni ^c   Lindblad, Marianne ^c   Fenyö, Eva Maria ^b   Holmgren, Jan ^c   Harandi, Ali M ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antivirals; Chemokines; CpG; CTB; HIV

Indexed keywords

ANTIBODY CONJUGATE; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE CHOLERA TOXIN B SUBUNIT CONJUGATE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

ANTIVIRAL ACTIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOSTIMULATION; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; REVIEW; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

CHEMOKINE CCL3; CHEMOKINE CCL4; CHOLERA TOXIN; CPG ISLANDS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNOCONJUGATES; LEUKOCYTES, MONONUCLEAR; OLIGONUCLEOTIDES; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS REPLICATION;

EID: 47749130824     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208784325038     Document Type: Review

References (39)

1. Devito C, Hinkula J, Kaul R, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-20.
2. Garzino-Demo A, DeVico AL, Cocchi F, Gallo RC. Beta-chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 1998; 14 Suppl 2:SI77-84.
3. Belec L, Ghys PD, Hocini H, et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001; 184:1412-22.
4. Cole AM. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006; 306:199-230.
5. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85:85-95.
6. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74:479-85.
7. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16:637-46.
8. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-60.
9. Adamsson J, Lindblad M, Lundqvist A, et al. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin. J Immunol 2006; 176:4902-13.
10. Harandi AM, Holmgren J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr Opin Investig Drugs 2004; 5:141-5.
11. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003; 77:953-62.
12. Harandi AM. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. J Clin Virol 2004; 30:207-10.
13. Pyles RB, Higgins D. Chalk C, et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 2002; 76:11387-96.
14. Ashkar AA, Bauer S, Mitchell WJ, et al. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol 2003; 77:8948-56.
15. Tengvall S, Lundqvist A, Eisenberg RJ, et al. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in. the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital-herpes. J Virol 2006; 80:5283-91.
16. Schlaepfer E, Audige A, von Beust B, et al. CpG oligodeoxynucleotides block human immunodefidency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 2004; 78:12344-54.
17. Back E, Svennerholm AM, Holmgren J, Mouby R. Evaluation of a ganglioside immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin. J Clin Microbiol 1979; 10:791-5.
18. Jansson M, Popovic M, Karlsson A, et al. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996; 93:15382-7.
19. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71:7478-87.
20. Albert J, Naucler A, Bottiger B, et al. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS 1990; 4:291-5.
21. Lazarus R, Klimecki WT, Raby BA, et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics 2003; 81:85-91.
22. El Andaloussi A, Sonabend AM, Han Y. Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006; 54:526-35.
23. Wu CC, Lee J, Raz E, et al. Necessity of oligonucleotide aggregation for toll-like receptor 9 activation. J Biol Chem 2004; 279:33071-8.
24. Yasuda K, Yu P, Kirschning CJ, et al. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and - independent pathways. J Immunol 2005; 174:6129-36.
25. Leifer CA, Kennedy MN, Mazzoni A, et al. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 2004; 173:1179-83.
26. Wang J, Alvarez R, Roderiquez G, et al. CpG-independent synergistic induction of beta-chemokines and a dendritic cell phenotype by orthophosphorothioate oligodeoxynucleotides and granulocyte-macrophage colony-stimulating factor in elutriated human primary monocytes. J Immunol 2005; 174:6113-21.
27. Vollmer J, Weeratna RD, Jurk M, et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 2004; 113:212-23.
28. Rodriguez JM, Elias F, Flo J, et al. Immunostimulatory PyNTTTTGT oligodeoxynucleotides: structural properties and refinement of the active motif. Oligonucleotides 2006; 16:275-85.
29. Matsukura M, Shinuzuka K, Zon G, et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication d cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 1987; 84:7706-10.
30. Field AK. Oligonucleotides as inhibitors of human immunodeficiency virus. Curr Opin Mol Ther 1999; 1:323-31.
31. Wyatt JR, Vickers TA, Roberson JL, et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci USA 1994; 91:1356-60.
32. Agatsuma T, Yamamoto I, Furukawa H, Nishigaki T. Guanine-rich oligonucleotide modified at the 5′ terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Antiviral Res 1996; 31:137-48.
33. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. Biodrugs 2007; 21:387-401.
34. Becker Y. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - A review, hypothesis and implications. Virus Genes 2005; 30:251-266.
35. Scheller C, Ullrich A, McPherson K, et al. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004; 279:21897-21902.
36. Shen J, Iwasaki A. A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide. J Clin Invest 2006; 116:2237-2243.
37. Equils O, Schito MI, Karahashi H, et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: Implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003; 170:5159-5164.
38. Scheller C, Ullrich A, Lamla S, et al. Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV - Reactivation of latent provirus and inhibition of productive infection in human T cells. Ann N Y Acad Sci 2006; 1091: 540-547.
39. Wang Y, Abel K, Lantz K, et al. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 2005; 79:14355-70.